Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong
Supernus Pharmaceuticals (SUPN) has shown strong returns over five years, with its stock price almost doubling, yet current valuations suggest it remains inexpensive. The company screens as undervalued on multiple checks, particularly on its Price/Sales (P/S) ratio compared to industry averages. The key question for investors is whether future revenue growth and product uptake will justify a re-rating closer to its peers, or if the current discount reflects concerns about margins and research spending.
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong
Supernus Pharmaceuticals (SUPN) has shown strong returns over the past five years, with its stock almost doubling, and still appears undervalued on several measures. Despite a 16.7% return over the last year, which lags behind peers, the company's P/S multiple of 3.4x is below the industry average, suggesting potential for re-rating if revenue growth and product uptake continue. The main debate for investors is whether the current valuation gap represents mispricing or a fair reflection of execution risk.
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to form a leading CNS-focused biopharmaceutical company. The all-stock, tax-free merger is expected to create $125 million in annual cost synergies within the first year and result in a diversified portfolio of 11 medicines across addiction, ADHD, depression, and Parkinson's disease. The combined entity projects $2.2 billion in net revenue and $888 million in adjusted EBITDA, aiming to enhance financial flexibility and pursue future growth opportunities.
Rice Hall James & Associates LLC Takes $22.80 Million Position in Supernus Pharmaceuticals, Inc. $SUPN
Rice Hall James & Associates LLC has acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by purchasing 490,221 shares valued at approximately $22.80 million, making it their 28th largest holding. Analyst sentiment for Supernus is a "Moderate Buy" with a consensus price target of $62.83, despite mixed recent ratings. The company recently reported quarterly revenue of $219.06 million, exceeding estimates, but posted an adjusted loss of $1.01 per share against expected earnings.
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to form a leading CNS-focused biopharmaceutical company. This tax-free merger of equals anticipates $125 million in annual cost synergies within the first year and will create a combined portfolio of 11 medicines across addiction, ADHD, depression, and Parkinson's disease. The combined entity is projected to have approximately $2.2 billion in net revenue and $888 million in adjusted EBITDA, aiming for enhanced growth opportunities and financial flexibility.
Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals
Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals, Inc., had 2,500 Performance Share Units (PSUs) vest on August 12, 2026. Following the vesting, 1,158 shares were withheld by the company at $46.57 per share to cover tax obligations. After these transactions, Bhatt directly owns 18,637 shares of Supernus common stock.
Supernus Pharmaceuticals (SUPN) CEO exercises PSUs, withholds shares for taxes
Supernus Pharmaceuticals CEO Jack A. Khattar exercised 29,849 Performance Share Units (PSUs) on August 12, 2026, converting them into common stock. Of these, 12,642 shares were withheld to cover tax obligations at a price of $46.57 per share. The transaction increased his direct common stock holdings, and he also indirectly holds 958,100 shares through the KBT Trust.
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax
Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, exercised 750 Performance Share Units (PSUs) on August 12, 2026, converting them into 750 shares of common stock. To cover tax withholding requirements associated with this vesting, 363 shares were withheld by the company at a price of $46.57 per share. Rubin's direct holdings now include 13,979 common shares, with an additional 251 shares acquired through the company's Employee Stock Purchase Plan.
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 86.2% in the second quarter, selling 457,443 shares and retaining 73,175 shares valued at $3.4 million. Despite this large sale, analyst sentiment for Supernus remains generally positive, with a "Moderate Buy" consensus rating and an average price target of $62.83. The stock opened at $47.87, up 2.1%, and has a market capitalization of $2.78 billion.
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc.
Indivior Pharmaceuticals (NasdaqGS: INDV) has agreed to merge with Supernus Pharmaceuticals, forming a new entity named Supernus, Inc., with shared leadership. This merger is expected to significantly reshape both companies' corporate governance and operations, especially concerning Indivior's buprenorphine-based treatments. Investors should watch the combined company's financials, particularly net debt and cash generation, post-completion, as the deal includes a new senior secured term loan and a special dividend.
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc.
Indivior Pharmaceuticals (INDV) has agreed to merge with Supernus Pharmaceuticals, forming a new entity named Supernus, Inc., with shared leadership from both companies. The merger will introduce a significant debt and a special dividend, impacting the combined company's financial structure and requiring close monitoring of its net debt and cash generation post-completion. This deal reshapes Indivior's focus beyond its buprenorphine-based treatments and integrates it into a broader neuroscience portfolio.
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc.
Indivior Pharmaceuticals (INDV) has agreed to merge with Supernus Pharmaceuticals, creating a new entity named Supernus, Inc. The combined company will feature a unified board and leadership team drawn equally from both firms. This merger aims to integrate Indivior's buprenorphine-based treatments for opioid dependence with Supernus's neuroscience portfolio, while also introducing new financial structures including a significant term loan and special dividend.
Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth
Supernus Pharmaceuticals, Inc. (SUPN) is highlighted as a prominent player in CNS therapies with a 31.19% projected upside based on analyst targets, despite recent challenges in profitability. The company boasts strong revenue growth of 32.40% and a healthy free cash flow, indicating potential for significant returns for growth-focused investors. Supernus's promising pipeline and positive analyst sentiment make it a stock worth watching in the biopharmaceutical sector.
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts
Argus has lowered its target price for Supernus Pharmaceuticals Inc. (SUPN) to $41.00, while the current stock price is $47.64. Supernus Pharmaceuticals specializes in developing and commercializing treatments for central nervous system diseases. Investors can access the full report with a Yahoo Finance Silver subscription.
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research
Zacks Research has upgraded Supernus Pharmaceuticals (NASDAQ:SUPN) from a "hold" to a "strong-buy" rating. This upgrade comes despite a broader analyst consensus of "Moderate Buy" with a target price of $62.83. The company, which specializes in central nervous system therapies, also saw several institutional investors, including Millennium Management, significantly increase their holdings in Q1.
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow
This article provides access to a slide deck published by Supernus Pharmaceuticals, Inc. concerning an M&A call related to Indivior Pharmaceuticals, Inc. The content is presented by SA Transcripts, a team responsible for developing and publishing earnings call transcripts on Seeking Alpha.
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a central nervous system-focused company with 11 marketed products and an expected annual revenue of $2.2 billion. The combined entity, which will operate as Supernus, anticipates $125 million in annual cost savings through "natural redundancies." Supernus CEO Jack Khattar will lead the new company, which aims for enhanced financial flexibility and future growth opportunities.
supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements
Supernus Pharmaceuticals, Inc. announced positive earnings pre-announcements, updating its fiscal year 2026 revenue range from $840-$870 Million to $860-$890 Million. The company has been active in mergers and acquisitions, including a proposed merger with Indivior and an acquisition of Sage Therapeutics, and has seen various FDA approvals and clinical trial developments for its treatments.
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ...
Supernus Pharmaceuticals Inc (SUPN) reported strong revenue growth in Q2 2026, driven by key product sales and advancements in its late-stage pipeline. Despite competitive pressures and increased R&D expenses, the company reaffirmed its full-year financial guidance, projecting net revenue between $640 million and $660 million. The Q&A session highlighted discussions on product growth, pipeline progress for SPN-820, competitive strategies for Qelbree, and the company's financial health with over $300 million in cash.
supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements
Supernus Pharmaceuticals, Inc. has pre-announced positive earnings, revising its fiscal year 2026 revenue guidance from an estimated $840-$870 million to $860-$890 million. This update highlights the company's financial performance and future projections. The article also provides a list of recent news related to Supernus, including mergers, quarterly results, and FDA approvals.
Supernus and Indivior merge to create scaled, CNS-focused entity
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on the central nervous system (CNS). The combined entity, which will operate under the name Supernus Inc. and trade on Nasdaq under 'SUPN', expects pro forma net revenue of $2.2 billion and $125 million in annual cost synergies. The merger will create a portfolio of 11 medicines for neurology, addiction, and psychiatry, with current Supernus CEO Jack Khattar leading the new company.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
Monteverde & Associates PC, a class action firm, has announced an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) concerning its proposed sale to Indivior Pharmaceuticals, Inc. The firm is examining whether the deal, where Supernus shareholders would receive 1.5401 common shares of Indivior for each Supernus share, is fair to shareholders. Shareholders are encouraged to contact the firm for more information about the investigation.
Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals
Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. Khattar serving as CEO. The merger aims to build a diversified platform with established commercial franchises, pipeline, R&D capabilities, and a strong financial profile, with closing expected in Q4 2026.
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Supernus Pharmaceuticals is set to report its Q2 earnings this Tuesday after market hours. Analysts expect the company's revenue to grow by 24.3% year-on-year, improving from the previous year's 5.6% increase. Despite Supernus Pharmaceuticals beating revenue expectations last quarter, it significantly missed EPS estimates, and its stock is currently down 5.5% over the last month.
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form Supernus, Inc., a new CNS-focused pharmaceutical company. The combined entity will have a portfolio of 11 commercialized products across addiction, ADHD, depression, and Parkinson's disease, with nearly $2.2 billion in revenue. This merger is described as a "merger of equals," aiming for a broader product portfolio and enhanced financial flexibility.
CNS-focused Supernus and Indivior agree merger terms
Supernus Pharma and Indivior have agreed to an all-stock merger, forming a new company, Supernus Inc., focused on CNS diseases with combined revenues of around $2.2 billion. The deal, expected to close in Q4, will see Indivior shareholders owning 56.5% of the new company and receiving a $1 billion cash dividend. Jack Khattar, current Supernus CEO, will lead the combined entity, which anticipates $125 million in annual cost savings.
Rockville's Supernus more than tripling size through merger of equals
Rockville's Supernus Pharmaceuticals is merging with Richmond-based Indivior in a "merger of equals" transaction. The combined company will be led by current Supernus CEO Jack Khattar and is expected to generate approximately $2.2 billion in annual revenue from nearly a dozen neurological and psychiatric drugs. This merger will significantly increase Supernus's size and market presence.
Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential breaches of fiduciary duty related to its transaction with Indivior Pharmaceuticals. Supernus shareholders are set to receive 1.5401 common shares of Indivior for each Supernus share, resulting in Supernus stockholders owning approximately 43.5% of the combined entity. The investigation focuses on whether the Supernus board fulfilled its fiduciary duties, especially concerning potential limitations on competing bids and benefits for insiders.
Supernus Pharmaceuticals Q2 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced an all-stock, tax-free merger of equals to create a CNS-focused biopharmaceutical company with an estimated $2.2 billion in pro forma revenue. The combined entity, which will retain the Supernus name and be headquartered in Rockville, Maryland, is expected to realize $125 million in annual cost synergies within the first year. The deal, anticipated to close in Q4 2026, aims to establish a CNS leader with 11 marketed medicines, including key growth products like SUBLOCADE, Qelbree, ZURZUVAE, GOCOVRI, and ONAPGO.
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock, tax-free transaction to create a leading diversified central nervous system (CNS) biopharmaceutical company. The combined entity, to be named Supernus, Inc., is expected to have approximately $2.2 billion in annual revenues and generate $125 million in annual cost synergies. Jack Khattar will serve as President and CEO, leading a company with an enhanced financial position and a diversified portfolio of CNS medicines.
Understanding Momentum Shifts in (SUPN)
This article analyzes Supernus Pharmaceuticals Inc. (SUPN) using AI models, highlighting a neutral near-term sentiment and potential mid-term weakness. It identifies a breakdown underway, suggesting lower levels and elevated downside risk. The report provides specific institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.
Supernus Pharmaceuticals (SUPN) awards 2,500 performance share units
Supernus Pharmaceuticals' Sr. VP of IP, CSO Padmanabh P. Bhatt, was awarded 2,500 Performance Share Units on July 29, 2026. These units, which were part of an award from February 19, 2025, vested upon the achievement of individual performance objectives set on May 3, 2025. This transaction, reported via a Form 4 SEC filing, represents equity compensation and increases Bhatt's direct holdings to 2,500 Performance Share Units.
Supernus Pharmaceuticals (NASDAQ: SUPN) CEO granted 29,849 performance share units
Supernus Pharmaceuticals CEO Jack A. Khattar was granted 29,849 Performance Share Units on July 29, 2026, which correspond to one share of common stock each. These units, awarded on February 19, 2025, vested upon the achievement of individual performance objectives established on May 3, 2025. This transaction, valued at $0.00 per unit as equity compensation, leaves the CEO holding 29,849 units from this specific award.
Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN)
This article provides an overview of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights key metrics such as market capitalization, earnings per share, revenue, and EBITDA, while also offering insights into the company's employee count and upcoming earnings release. The content serves as a resource for investors to conduct their own research on SUPN stock.
Supernus Pharmaceuticals (NASDAQ: SUPN) CMO receives 750 performance share units
Jonathan Rubin, SVP and Chief Medical Officer at Supernus Pharmaceuticals (NASDAQ: SUPN), was granted 750 Performance Share Units on July 29, 2026. These units, part of an award from February 2025, vested upon the achievement of specific individual performance objectives set in May 2025. This insider transaction highlights equity-based compensation tied to performance, with the units corresponding to 750 shares of common stock.
Supernus Pharmaceuticals Inc (SUPN) Financial Health: Profitability & Balance Sheet Analysis
Supernus Pharmaceuticals Inc (SUPN) currently holds a financial score of 7.52, ranking 111th out of 155 in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $207.71 million, marking a 38.63% year-over-year increase, and an 80.61% rise in net profit. While these figures highlight strong performance, specific granular data for categories like cash and cash equivalents, total assets, operating profit, and free cash flow have not yet been disclosed by the company.
Supernus Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
Supernus Pharmaceuticals (NASDAQ: SUPN) had 793 employees as of March 2026, representing a 25.8% decline from 2023. The company is actively hiring, with 105 job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but improving, and the average salary is $132,261.
How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Positive Earnings ESP And Renewed Beat Expectations
Supernus Pharmaceuticals (SUPN) is attracting investor attention due to a positive Earnings ESP and a history of beating earnings expectations ahead of its early August 2026 release. While this fuels optimism for another beat, the core investment narrative relies on the company's ability to achieve its 2026 revenue and operating earnings guidance and manage ongoing risks like pricing pressure. Analysts highlight the importance of the upcoming report in shaping confidence in Supernus's ambitious CNS growth plans, despite varying fair value estimates among community members.
How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Positive Earnings ESP And Renewed Beat Expectations
Supernus Pharmaceuticals (SUPN) has garnered attention due to a positive Earnings ESP and past outperformance, leading to optimism about its upcoming earnings report. The company's investment narrative centers on its ability to turn its CNS portfolio into sustainable profitability while managing risks like pricing pressure and dependence on key drugs. While a strong earnings report could boost confidence in Supernus's execution, investors are encouraged to consider diverse fair value estimates and the company's reliance on a limited product range.
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?
Supernus Pharmaceuticals (SUPN) is projected to report a year-over-year decline in earnings but higher revenues for the quarter ended June 2026. The company has an Earnings ESP of +18.52% and a Zacks Rank #3, indicating a high probability of beating the consensus EPS estimate of $0.54 per share. This analysis suggests Supernus is a compelling candidate for an earnings beat based on Zacks' proprietary surprise prediction model.
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?
Supernus Pharmaceuticals (SUPN) is expected to show an earnings decline year-over-year but with increased revenues for the quarter ending June 2026. With a positive Zacks Earnings ESP of +18.52% and a Zacks Rank #3, the company is likely to beat the consensus EPS estimate. Investors should consider these factors and other market conditions before making investment decisions.
Supernus Pharmaceuticals, Inc. Revenue Breakdown – GETTEX:S49
Supernus Pharmaceuticals, Inc. (GETTEX:S49) generated 612.13 million EUR in revenue last year, primarily from its Central Nervous System Disease Treatments segment. The United States was the company's largest regional contributor to this revenue. This financial data shows a slight decrease from the previous year's revenue of 639.30 million EUR.
Supernus Pharmaceuticals (SUPN) Could Be 25% Undervalued On Rising Earnings Expectations
Supernus Pharmaceuticals (SUPN) is considered undervalued by 25% due to rising earnings expectations, with a positive Earnings ESP of 18.52% and a history of beating estimates. Analysts peg the fair value at $62.83, significantly higher than its current share price of $46.98. This valuation is driven by an expanding patient pool for its core products, Qelbree and GOCOVRI, which is expected to fuel revenue growth and margin improvement.
Supernus Pharmaceuticals Inc (SUPN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Supernus Pharmaceuticals Inc (SUPN) focusing on its dividend and stock split history. It notes that the company has not distributed dividends totaling 0.00 USD over the past five years and contains no data on past dividend payments or stock splits.
Supernus Pharmaceuticals Inc (SUPN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article provides a detailed revenue breakdown for Supernus Pharmaceuticals Inc (SUPN), presenting its financial performance by business segments and regional contributions. The data covers various fiscal years and quarters, highlighting key product sales such as Qelbree, GOCOVRI, APOKYN, and Trokendi XR, along with collaboration revenue and other income. The regional revenue indicates that the United States accounts for 100% of the company's reported revenue.
SUPN|Supernus Pharmaceuticals Inc|Price:47.496|Chg%:+1.296
Supernus Pharmaceuticals Inc (SUPN) shows healthy fundamentals and high growth potential, despite a recent turnaround to a loss. The stock is considered fairly valued within the Pharmaceuticals industry, with high institutional ownership and multiple "Buy" ratings from analysts, setting a highest price target of $63.50. The price is currently range-bound, suggesting suitability for swing trading.
Supernus CEO and CFO to host Aug. 4 second-quarter webcast
Supernus Pharmaceuticals announced that its CEO, Jack Khattar, and CFO, Tim Dec, will host a conference call and webcast on August 4, 2026, at 4:30 p.m. ET to discuss the company's second-quarter 2026 financial and business results. The results will be reported after the market closes on the same day. A replay of the webcast will be available for 60 days on the company's Investor Relations website.
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
Supernus Pharmaceuticals, Inc. announced that it will report its second-quarter 2026 financial and business results after market close on Tuesday, August 4, 2026. Following the report, President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET to discuss the findings and answer questions. A replay of the webcast will be available on the company's investor relations website for 60 days.
Supernus Pharmaceuticals to Announce Second Quarter 2026
Supernus Pharmaceuticals, Inc. announced it will release its second quarter 2026 financial and business results on Tuesday, August 4, 2026, after market close. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results, led by President and CEO Jack Khattar and SVP and CFO Tim Dec. A replay of the webcast will be available on the company's investor relations website for 60 days.
Supernus Pharmaceuticals to Announce Q2 2026 Earnings and Host Conference Call on August 4
Supernus Pharmaceuticals will release its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026. This announcement will be followed by a conference call and webcast at 4:30 p.m. Eastern Time. Investors will have the opportunity to hear directly from management regarding the company's operational performance and financial metrics for the first half of 2026.
